EUVIMEDEUVIMED entdecken
Crossref

Elevated levels of nitrotyrosine-modified protein adducts and their association with the severity of primary sjogren’s syndrome and secondary sjogren’s syndrome with rheumatoid arthritis in Taiwanese Patients

Hao-En Teng, Yi-Hsuan Tsai, Ya-Ching Mo, Yu-Ju Lu, Hung-Tse Lin, Yu-Sheng Chang, Ching-Yu Lin

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-025-07730-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Hao-En Teng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, 11031, Taiwan. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Arthritis, Rheumatoid, Tyrosine, Autoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Taipei Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Primary Sjogren's syndrome (pSS) is an autoimmune condition characterized by glandular dysfunction. The roles of nitrotyrosine-modified (NT)-protein adducts and anti-NT-peptide adduct autoantibodies in disease progression and their potential as biomarkers remain underexplored. In this study, we assessed NT-protein adducts, related autoantibodies, and their associations with disease progression in pSS patients and their transformation into secondary SS with rheumatoid arthritis (RA-sSS). METHODS: The serum levels of proteins, NT-protein adducts, and autoantibodies against novel pSS-specific component C3 (C3)914-926 and C4b-binding protein alpha chain (C4BPA)336-353 were analyzed via proteomics and immunoassays. The statistical significance of the odds ratios (ORs) was estimated. Biomarker combinations were assessed for diagnostic performance. RESULTS: NT-protein adduct levels progressively increased across groups, reflecting increasing nitrosative stress. Elevated NT-protein adducts (OR = 4.542) and reduced levels of specific autoantibodies, such as IgA anti-C3914-926 (OR = 12.503), IgA anti-C3914-926 NT (OR = 12.758), IgA anti-C4BPA336-353 (OR = 15.962), IgM anti-C4BPA336-353 NT (OR = 2.471), and IgG anti-C4BPA336-353 NT (OR = 5.302), were identified as risk factors for disease progression in patients with pSS; in particular, NT-protein adducts (OR = 8.005) increased disease transformation to RA-sSS. LightGBM achieved the highest performance (AUC = 0.991) in distinguishing pSS from HCs, whereas XGBoost performed best (AUC = 0.876) in differentiating pSS from RA-sSS. CONCLUSIONS: Our findings suggest that elevated NT-protein adducts may signify an increased risk for disease progression in pSS patients and transformation to RA-sSS. Machine learning integration of NT-protein adducts, autoantibodies, and traditional biomarkers may enhance early SS diagnosis. Key Points • The elevated nitrotyrosine-modified protein adducts may emerge as significant biomarkers of disease progression in pSS and its transformation into RA-sSS.. • The reduced specific autoantibodies, such as IgA anti-C3914-926, IgA anti-C3914-926 NT, IgA anti-C4BPA336-353, IgM anti-C4BPA336-353 NT, and IgG anti-C4BPA336-353 NT, were associated with increased risks of disease progression in pSS. • Integration of NT-protein adducts, autoantibodies, and traditional biomarkers enhances diagnostic accuracy for SS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeArthritis, RheumatoidTyrosineAutoantibodiesHumansFemaleMiddle AgedMaleBiomarkersTaiwanAdultDisease ProgressionAgedSeverity of Illness IndexProteomics

Stichwörter der Autor:innen

Autoantibody isotypeNitrotyrosinePrimary Sjogren’s syndromeSecondary Sjogren’s syndrome with rheumatoid arthritis

Substanzen

3-nitrotyrosineTyrosineAutoantibodiesBiomarkers

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, 11031, Taiwan.
  • Department of Family Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, 11696, Taiwan.
  • Department of Laboratory Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 23561, Taiwan.
  • School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.
  • Department of Laboratory Medicine, LinKou Chang Gung Memorial Hospital, Taoyuan, 33305, Taiwan.
  • Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan.

Förderung

  • Taipei Medical University Hospital

Zitieren

APA

Teng, H. E., Tsai, Y. H., Mo, Y. C., Lu, Y. J., Lin, H. T., Chang, Y. S., & Lin, C. Y. (2026). Elevated levels of nitrotyrosine-modified protein adducts and their association with the severity of primary sjogren’s syndrome and secondary sjogren’s syndrome with rheumatoid arthritis in Taiwanese Patients. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07730-3

Vancouver

Teng HE, Tsai YH, Mo YC, Lu YJ, Lin HT, Chang YS, et al. Elevated levels of nitrotyrosine-modified protein adducts and their association with the severity of primary sjogren’s syndrome and secondary sjogren’s syndrome with rheumatoid arthritis in Taiwanese Patients. Clinical Rheumatology. 2026. doi:10.1007/s10067-025-07730-3

BibTeX
@article{Teng2026,
  author = {Teng, Hao-En and Tsai, Yi-Hsuan and Mo, Ya-Ching and Lu, Yu-Ju and Lin, Hung-Tse and Chang, Yu-Sheng and Lin, Ching-Yu},
  title = {Elevated levels of nitrotyrosine-modified protein adducts and their association with the severity of primary sjogren’s syndrome and secondary sjogren’s syndrome with rheumatoid arthritis in Taiwanese Patients},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-025-07730-3}
}
Kostenlos starten →